Because tumor cells are known to induce T-cell ... CAR transmembrane domain to enhance the immune synapse, offers an avenue for enhancing CAR-T therapy. By optimizing the immune synapse without ...

1). “CO-CTEs are designed to organize co-stimulatory proteins around the binding site on the CAR to mimic the canonical T-cell immune synapse,” said Rennert. “By inducing immune synapse ...

Ahmed Gad, postdoctoral associate in Ahmed's lab, the research team examined molecular dynamics at the immune synapse. The team biopsied the CAR T cell immunological synapse by isolating the ...

8 (6) Soluble TCR and TCR mimics are small proteins that bind peptides and engage with the CD3ε subunit of the endogenous TCR to create a synthetic immunological synapse. 9,10 (7) A T cell antigen ...

For their most effective indications, CAR T cells are effective serial killers; each CAR T cell can recognize and lyse several tumor cells. Moreover, what supports the energy cost of synapse formation ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to co-develop the prospect, BioNTech let the option expire as part of its ...

View Full Profile. Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment ...